Aug. 31 (Bloomberg) -- Novartis AG's Sandoz unit, the world's second-biggest maker of generic drugs, became the first company to win approval for a biological copy of Johnson & Johnson's Eprex anemia treatment, allowing it to offer cheaper versions to Europeans.
